Example: Heart Attack

Clinical Trials on Spinal Muscular Atrophies of Childhood

Total 20 results

    • NCT03395795
      Recruiting
      Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II
      Conditions: Infantile Spinal Muscular Atrophy
    • NCT01611610
      Completed
      Clinical Assessment of Spinal Muscular Atrophy Type II and III (SMA Europe)
      Conditions: Spinal Muscular Atrophy
    • NCT03837184
      Active, not recruiting
      Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
      Conditions: Spinal Muscular Atrophy Type I
    • NCT01862042
      Completed
      Palliative Care in Spinal Muscular Atrophy (SMA) 1
      Conditions: Spinal Muscular Atrophy 1
    • NCT02227823
      Unknown status
      Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
      Conditions: Spinal Muscular Atrophy Type 3
    • NCT02122952
      Completed
      Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
      Conditions: Spinal Muscular Atrophy 1
    • NCT00661453
      Completed
      CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I
      Conditions: Spinal Muscular Atrophy Type I
    • NCT03709784
      Recruiting
      Spinraza in Adult Spinal Muscular Atrophy
      Conditions: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type 3
    • NCT00439218
      Terminated
      Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I
      Conditions: Spinal Muscular Atrophy Type I
    • NCT00439569
      Terminated
      Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III
      Conditions: Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III
    • NCT03421977
      Active, not recruiting
      Long-Term Follow-up Study for Patients From AVXS-101-CL-101
      Conditions: Spinal Muscular Atrophy 1
    • NCT01302600
      Completed
      Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
      Conditions: Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III Non Ambulant
    • NCT00568698
      Completed
      A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients
      Conditions: Muscular Atrophy, Spinal
    • NCT00568802
      Completed
      A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients
      Conditions: Muscular Atrophy, Spinal
    • NCT04042025
      Enrolling by invitation
      Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
      Conditions: Spinal Muscular Atrophy Type I; Spinal Muscular Atrophy Type II; Spinal Muscular Atrophy Type III; SMA
    • NCT02941328
      Completed
      SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4
      Conditions: Spinal Muscular Atrophy; SMA; Kugelberg-Welander Disease
    • NCT02855112
      Unknown status
      Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients
      Conditions: Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]
    • NCT02061189
      Active, not recruiting
      Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA)
      Conditions: Infantile Spinal Muscular Atrophy of Type 2 or 3
    • NCT03921528
      Active, not recruiting
      An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
      Conditions: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2; SMA; Neuromuscular Diseases; Muscular Atrophy; Atrophy; Muscular Atrophy, Spinal; Neuromuscular Manifestations
    • NCT04690998
      Not yet recruiting
      Outcome Measures and Biomarkers in a Cohort of Spinal Muscular Atrophy Type III/ IV Patients
      Conditions: Amyotrophic Lateral Sclerosis
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations